Notice of Change in RFA-HL-13-016, NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44) , to Allow Resubmissions

Notice Number: NOT-HL-12-141

Release Date: April 17, 2012

National Heart, Lung, and Blood Institute (NHLBI)

This Notice is to inform potential applicants that the NHLBI is revising RFA-HL-13-016, "NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44) to allow resubmission of Phase IIB Competing Renewal applications that were previously submitted in response to the Omnibus PA (PA-12-088 and prior).

The following correction to this FOA is being made:

Application Types Allowed

Phase IIB Competing Renewal (Phase IIB, formerly Phase II Competing Renewal)

Resubmission (Phase IIB previously submitted under this FOA only)

The OER Glossary and the SF424 (R&R) SBIR/STTR Application Guide provide details on these application types.

Phase IIB Competing Renewal (Phase IIB, formerly Phase II Competing Renewal)

Resubmission

The OER Glossary and the SF424 (R&R) SBIR/STTR Application Guide provide details on these application types.

All other aspects of the FOA remain unchanged and applicants must meet all requirements of RFA-HL-13-016.

Please direct all inquiries to:

Kurt W. Marek, PhD
Office of Translational Alliances and Coordination
Division of Extramural Research Activities
National Heart, Lung, and Blood Institute
6701 Rockledge Drive
Bethesda, MD 20892-7922 (Express mail zip: 20817)
Telephone: (301) 443-8778
FAX: (301) 480-0422
Email: [email protected]